2．疗效评价［19,20］：在乙酰胆碱酯酶抑制剂特可林（tacrine)、velnacrine 、毒扁豆碱（physostigmine)、多奈哌齐（donepezil)和rivastigmine治疗轻-中度AD的大样本、多中心、随机、双盲、安慰剂对照临床试验中，疗效评价均采用MMSE、ADAS-cog分测验和临床晤谈总体印象量表。Arrieta等［20］总结1981～1997年公开发表的49篇特可林治疗AD的论文，应用的评定工具为：MMSE 16篇，ADAS 4篇，3MS、CASI、AVLT等均有报道。
六、几点说明
1． 上述量表对于确定痴呆的病因即鉴别诊断方面作用有限。
2． 从55或60岁开始纵向随访认知功能十分重要，尤其是教育程度比较高的老人。
3． 认知评定只能作为AD诊断的辅助工具，临床诊断必须结合日常活动能力量表、非认知行为问卷、总体严重度量表、照料者负担量表及脑影像学、电生理学、生化学检查结果，最后确诊依赖于随访和病理检查。
4. 躯体状况不佳、情绪障碍、意识不清、受试者不配合等都可以影响认知检查结果。
5. 时代在发展，人口的年龄结构和老人素质处在变化之中，对认知功能的认识也在深化，故评定工具也需要不断修订以适应新的要求。由于知识产权等原因，上述大部分测验没有引进。我们介绍这些评定方法，供国内同道在量表编制与使用时参考。
参考文献
1，Tierney MC, Szalai JP, Snow WG, et al. Domain specificity of the subtests of the mini-mental state examination. Arch Neurol, 1997,54:713-716.
2，Stuss DT,Meiran N,Guzman DA，et al. Do long tests yield a more accurate diagnosis of dementia than short tests Arch Neurol, 1996,53:1033-1039.
3，郑瞻培. 修改后的长谷川简易智能评定量表. 国外医学精神病学分册，1993，20： 40-41.
4，Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry, 1998, 64:588-594.
5，Solomon PR, Hirschoff A, Kelly B, et al. A 7 minute neurocognitive screening battery: highly sensitive to Alzheimer′s disease. Arch Neurol, 1998, 55:349-355.
6，Lezak MD. Neuropsychological assessment.2nd ed. New York: Oxford University Press, 1983.578-581.
7，Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer′s disease. Am J Psychiatry, 1984, 141:1356-1364.
8，Kiernan RJ, Mueller J, Langston JW, et al. The neurobehavioral cognitive status examination: a quantitative approach to cognitive assessment. Ann Intern Med,1987,107:481-485.
9，Osmon DC, Smet IC, Winegarden B,et al. Neurobehavioral cognitive status examination: its use with unilateral stroke patients in a rehabilitation setting. Arch Phs Med Rehabil, 1992,73:414-418.
10，Faust D, Fogel B. The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis, 1989, 177:25-31.
11，Glosser G, Wolfe N, Kliner-Krenzel L, et al. Cross-cultural cognitive examination performance in patients with Parkinson′s disease and Alzheimer′s disease. J Nerv Ment Dis, 1994, 182: 432-436.
12，Mate-Kole CC, Major A, Lenzer I, et al. Validation of the quick cognitive screening test. Arch Phys Med Rehabil, 1994,75:867-875.
13，Delis DC. Neuropsychological assessment of learning and memory. In: Boller F, Grafman J, eds. Handbook of Neuropsychology. vol.3. New York: Elsevier Science Publishers B.V. （Biomedical Division), 1989.3-30.
14，Chan AS,Salmon DP,Butters N, et al. Semantic network abnormality predicts rate of cognitive decline in patients with probable Alzheimer′s disease. J Int Neuropsychol Soc, 1995, 1:297-303.
15，Chan AS,Butters N,Salmon DP. The deterioration of semantic networks in patients with Alzheimer′s disease: a cross-sectional study. Neuropsychologia, 1997, 35:241-248.
16，Morris JC,Heyman A,Mohs RC,et al. The Consortium to Establish a Registry for Alzheimer′s Disease（CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer′s disease. Neurology, 1989,39:1159-1165.
17，Almkvist O. Neuropsychological features of early Alzheimer′s disease: preclinical and clinical stages. Acta Neurol Scand, 1996, 165 Suppl: 63-71.
18，Pasquier F. Early diagnosis of dementia: neuropsychology. J Neurol, 1999,246:5-15.
19，Francis PT,Palmer AM,Snape M, et al. The cholinergic hypothesis of Alzhemer′s disease: a review of progress. J Neurol Neurosurg Psychiatry, 1999, 66:137-147.
20，Arrieta JL, Artalejo FR. Methodology,results and quality of clinical trials of tacrine in the treatment of Alzheimer disease: a systematic review of the literature. Age Aging, 1998,27:161-179.
